Omega-3 Polyunsaturated Fatty Acid Intake May Reduce Risk of ALS
the Neurology Advisor take:
Omega-3 polyunsaturated fatty acid intake may reduce the risk of developing amyotrophic lateral sclerosis (ALS), according to findings from a national study that involved more than 1 million patients.
As ALS cannot yet be prevented or cured, researchers explored the association between consumption of omega-6 and omega-3 polyunsaturated fatty acids (PUFA), which incorporate in brain lipids and modulate oxidative and inflammatory processes, and ALS risk.
The study, published in JAMA Neurology, assessed the diets of nearly 480,000 women and 523,000 men from five cohorts, including subjects from the National Institutes of Health-AARP Diet and Health Study, the Cancer Prevention Study II Nutrition Cohort, the Multiethnic Cohort Study, the Health Professionals Follow-up Study and the Nurses’ Health Study, to formulate risk ratios of ALS incidence or death. Overall, there were 995 cases of ALS documented in the study cohort.
Greater intake of omega-3 PUFA was associated with a lower risk of developing ALS, whereas consumption of omega-6 PUFA was not associated with ALS risk, the researchers found. The multivariable-adjusted risk ratio for the highest to lowest quintile of the omega-3 PUFA intake was 0.66 (95% CI: 0.53-0.81; P<0.001 for trend).
The results indicate that consumption of foods high in omega-3 PUFA may help to prevent or delay the onset of ALS.
Omega-3 fatty acid
Alberto Ascherio, MD, DrPH, of the Department of Nutrition at Harvard School of Public Health, in Boston, Massachusetts, and colleagues examined the association between ω-6 and ω-3 PUFA consumption and ALS risk in longitudinal analyses that included five prospective cohorts.
Next Article in Neurodegenerative Diseases
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies